South San Francisco, California., February 10, 2025 /PRNewswire/ -IdeayyaBiosciences, Inc. (NASDAQ: IDYA) is a precision medical oncology company working to discover and develop targeted therapies Joshua Brehalskias Chief Financial Officer of PhD. Dr. Bleharski joined JP Morgan's Ideaya where for nearly 17 years he advised clients in the Biopharma sector on capital market trading, corporate strategies and other investment banking services. Ideaya expects Dr. Bleharski will complete his transition to his new role by early May.
“We welcome Josh to the idea as we advance our wide range of potential classes of precision medical oncology pipelines and build a fully integrated biotechnology company. And “It's an invaluable strategic transaction experience in driving our vision to build an industry-leading precision medical oncology company.” Yujiro S. HataPresident and CEO of Ideayya Biosciences.
“We are excited to join Ideaya during this exciting stage of growth. This is through India's well-known research across multiple solid tumor indications, with six potential first-class clinical programs and three previous ones. I look forward to working with their team to advance the clinical program. Dr. Bleharski is a key precision focused on scientific innovation and highly unmet medical needs of cancer. Talented and dedicated experts dedicated experts to realize our collective vision of building a medical oncology company “I'm becoming like a professional expert at home.”
Prior to Ideayya, Dr. Bleharski was the managing director and global co-head of Biopharma at JP Morgan's Healthcare Investment Banking Group. During his banking career, he advised many funding and strategic transactions. $65 billion Value for biotech companies all over the world. Early in his career, he worked as a senior staff scientist at a private biotech company San Diego He was a postdoctoral researcher at the La Jolla Institute of Allergy and Immunology (LIAI) and the UCLA School of Medicine. Dr. Bleharski owns BS in Biology Duke UniversityImmunology from PhD University of California, Los Angeles And the HAAS School of Business MBA University of California, Berkeley.
About Ideayya Biosciences
Ideaya is a precision medical oncology company committed to discovering and developing targeted treatments for selected patient populations using molecular diagnostics. Ideayya's approach integrates the ability to identify and validate integrated biomarkers and select the patient population that is most likely to benefit from the targeted therapy. Ideaya applies research and drug discovery capabilities to synthetic lethality. This represents a new class of precision medical goals.
Forward-looking statements
This press release contains forward-looking statements relating to advances in clinical and pre-clinical programs and the potential commercialization of their products. Ideaya has no obligation to update or modify any forward-looking statements. For more information about the risks and uncertainties that may cause actual results, please see the results expressed in these forward-looking statements and the risks related to Ideayya's business in general, please see Ideayya's annual See the chronicles in Report 10-k. February 20, 2024 Current and regular reports filed with the Securities and Exchange Commission.
Investor and Media Contacts
Ideayya Biosciences
Andres Louis Briceno
SVP, Head of Financial and Investor Relations
(Email protection)
Source: Ideayya Biosciences, Inc.
